Mirum Pharmaceuticals MIRM 深 滬
等待開盤 12-12 09:30:00 美东时间
64.90
+0.230
+0.36%
華盛通- 最 高66.77
- 今 開65.63
- 成交量 13.48万股
- 最 低 64.39
- 昨 收 64.67
- 總市值 32.60亿
- 52周最高 78.5445
- 市盈率 靜 --
- 換手率 0.27%
- 52周最低 36.8801
- 委 比 72.41%
- 總股本 5023.76万
- 歷史最高 78.5445
- 量 比 0.70
- 振 幅 3.68%
- 歷史最低 6.513
- 每 手 1
- 風險率 12.52%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
12-10 10:33
Evercore ISI Group Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $94
Evercore ISI Group analyst Gavin Clark-Gartner maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $89 to $94.
12-09 23:29
Mirum expands into liver diseases with Bluejay Therapeutics acquisition
Mirum Pharmaceuticals (MIRM) will expand its existing rare disease pipeline with liver disease candidates following its acquisition of privately held Bluejay Therapeutics. Deal terms call for Mirum to...
12-09 00:23
Mirum Pharmaceuticals Enrolls First Participant Enrollment In Bloom Phase 2 Study Evaluating MRM-3379 For Fragile X Syndrome
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that the first participant has been enrolled in the BLOOM Phase 2 clinical study evaluating MRM-3379 in Fragile X syndrome
12-01 21:15
Mirum Pharmaceuticals Receives Paragraph IV Notice From Sandoz On Livmarli; Sandoz Alleges Five Livmarli Patents Invalid Or Unenforceable; To File Patent Infringement Suit Against Sandoz
On November 17, 2025, Mirum Pharmaceuticals, Inc. (the "Company") received a Paragraph IV Certification Notice Letter (the "Notice Letter") from Sandoz, Inc. ("Sandoz") providing notification to the Company that Sandoz
11-18 05:57
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $81
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $80 to $81.
11-05 19:32
Earnings Scheduled For November 4, 2025
Companies Reporting Before The Bell • Sequans Communications (NYSE:SQNS) is lik...
11-04 19:12
Mirum Pharmaceuticals’ Volixibat Study: A Potential Breakthrough for PBC Itching
Mirum Pharmaceuticals (($MIRM)) announced an update on their ongoing clinical s...
10-28 06:29
